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ABSTRACT
Heat shock transcription factor 1 (HSF1), a key regulator of the heat-shock 
response, is deregulated in many cancers. HSF1 can mediate cancer cell survival and 
metastasis. High levels of HSF1 have been associated with poor prognosis in breast 
cancer. The nature of HSF1 upregulation needs to be validated in different cohorts to 
further validate its prognostic utility in breast cancer.
We first evaluated its expression in a cohort of breast cancer tissue microarrays 
with Oncotype DX recurrence scores available using immunohistochemistry. To further 
confirm the clinical relevance and prognostic impact, mutational and methylation 
status of the gene were also assessed in The Cancer Genome Atlas and publically 
available microarray datasets.
Immunohistochemical analysis showed that HSF1 expression is independent of 
Oncotype DX high recurrence score in ER-positive node-negative patients. Analysis 
of The Cancer Genome Atlas data revealed upregulation of HSF1 is not due to 
methylation or mutation. HSF1 copy number variations and amplifications (15%) were 
not associated with survival. In publicly available microarray datasets, a prognostic 
impact was observed in ER-positive tumors, but not in ER-negative tumors. Patients 
with ER-positive tumors with high HSF1 levels were associated with shorter overall 
survival (P = 0.00045) and relapse-free survival (P = 0.0057). In multivariable 
analysis, HSF1 remained a significant prognostic parameter.
The mRNA expression levels of HSF1 in ER-positive breast cancer are associated 
with both shorter relapse-free and overall survival. This prognostic impact is specific 
to mRNA expression, but stayed insignificant by protein expression or by analyzing 
amplification events. 
INTRODUCTION
Cells and organisms respond to stress by inducing 
heat shock proteins which act as molecular chaperones 
to restore protein homeostasis [1–4]. This adaptive 
mechanism is controlled by heat shock transcription 
factor (HSF1). When this transcription factor is activated, 
it gets phosphorylated, trimerized, and translocates to the 
nucleus. In the nucleus, it binds to specific DNA sequence 
motifs (known as heat shock elements) leading to the 
synthesis of heat shock proteins. In most experimental 
models, HSF1 enables adaptive changes in a diverse array 
of cellular processes including signal transduction, glucose 
metabolism and protein translation [5–10]. The binding of 
HSF1 to the DNA is dramatically different based on the 
phase of the cell cycle. HSF1 binds to only 35 target sites 
in mitotic chromatin, as opposed to 1242 target sites in 
freely cycling cells [11]. Its ability to activate transcription 
in mitosis is minimal. Consequently, mitotic cells are 
unable to induce expression of heat shock genes and are 
susceptible to protein damaging stress. 
Cancer cells, being mutation prone and aneuploid, 
show a high activity of HSF1. Recently, Mendillo et al. 
identified genomewide target sites of HSF1 in breast 
cancer cell lines with different metastatic capacities [12]. 
They showed that HSF1 driven transcription is profoundly 
different in malignant cells compared with cells that are 
exposed to heat stress. Cancer cells seem to “hijack” 
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HSF1 and utilize its transcriptional activity and central 
role in homeostasis to promote their growth and metastatic 
potential [13]. The importance of HSF1 in carcinogenesis 
is demonstrated by the dramatic reduction in susceptibility 
of HSF1-knockout mice to a wide spectrum of carcinogens 
[5, 14]. Similarly, depletion of HSF1 leads to marked 
decrease in proliferation and survival in established human 
cancer of cell lines [5, 9, 10, 14].
The role of HSF1 in breast cancer is not well 
established. Xi et al. have documented that deletion 
of HSF1 in mice overexpressing ERBB2 significantly 
reduces mammary tumorigenesis [15]. In addition the 
mice show a significant reduction in lung metastasis. 
Santagata et al. analyzed the expression of HSF1 
in breast cancer samples from the Nurses’ Health 
Study using immunohistochemistry [16]. They have 
documented an association of high HSF1 expression 
with increased mortality particularly in ER-positive 
patients (HR 2.1; P < 0.0001). They have postulated 
that targeting HSF1 might be a useful therapeutic 
strategy. In contrast Cheng et al. did not find HSF1 to 
be important in multivariate analysis in breast cancer. In 
the current study, we focus on validating these findings 
using data from publicly available gene expression 
databases, including The Cancer Genome Atlas (TCGA), 
as well as by performing immunohistochemistry using 
a commercially available antibody. We confirmed that 
high expression of HSF1 mRNA, but not amplification, 
is associated with poor prognosis. However, we found 
only a weak association between protein expression and 
high Oncotype DX recurrence scores, a surrogate for 
adverse outcomes. 
RESULTS
Upregulation HSF1 protein levels is independent 
of Oncotype DX high recurrence scores 
Analysis of the National Surgical Adjuvant 
Breast and Bowel Project (B14 and B20) clinical 
trials has led to the development of the Oncotype 
DX recurrence score [20]. This score estimates the 
likelihood of disease recurrence in women with early-
stage, ER-positive breast cancer and has been used as 
a surrogate for predicting outcomes. To validate the 
prognostic relevance of HSF1 observed by Santagata 
et al, we assessed the expression levels of HSF1 in a 
TMA cohort of patients with Oncotype DX scores using 
a commercially available antibody (see Materials & 
Methods) [16]. Immunohistochemistry results for HSF1 
expression (Figure 1) were assessable for 161 (77.6% 
of 210) patients (87 low; 54 intermediate and 20 high 
Oncotype DX scores). As shown in Table 1, there was 
no association between Oncotype DX score and staining 
intensity (P = 0.23), percentage (less or more 10%; 
P = 0.17), or H-score (above or below 70; P = 0.08). 
HSF1 expression and copy number alterations in 
primary breast tumors
We next analyzed the genomic alterations in TCGA 
breast cancer dataset (cBio Cancer Genomics Portal). 
Copy number alterations (CNA) of HSF1 were observed 
in 146 (15%) out of 962 breast tumors (Figure 2A–2C). 
Of these, 14.8% were due to amplification and 0.2% due 
to homozygous deletion. In addition, only 0.2% patients 
had mutations which were not located in major domains 
(Figure 2D). Of the tumors with altered HSF1 expression, 
upregulation (25.6%) was more prevalent rather than 
downregulation (0.1%) (Figure 2E). These analyses 
confirm that amplification is the most common alteration, 
while mutations of HSF1 are not frequent in breast cancer. 
Survival analysis of cases with and without amplifications, 
in all 962 patients or ER+ and ER- subsets did not show an 
association with overall survival or disease-free survival 
in TCGA dataset (Supplementary Figure S1). We further 
analyzed 737 out of 1079 cases available with methylation 
data (HM450). Methylation was inversely associated 
with the expression of HSF1 but the correlation was 
weak (Spearman 0.45; Figure 2F). However, cases with 
alterations versus without alterations did not significantly 
correlate with the overall survival or disease-free survival 
in TCGA dataset (Supplementary Figure S1).
High expression of HSF1 correlates with poor 
prognosis in patients with ER-positive breast 
cancer – The Affymetrix microarray datasets
The current study differed from the Santagata 
study in that a monoclonal antibody was used for the 
immunohistochemical analysis [16]. To further analyze 
whether the observed differences could be related to 
technical issues or biologic relevance, we next evaluated the 
prognostic value of HSF1 mRNA expression using overall 
survival and relapse-free survival as endpoints in subsets 
of breast cancer represented in 11 microarray datasets 
(GOBO tool). High expression of HSF1 was significantly 
associated with shorter overall survival (ANOVA; P = 
0.00045), and relapse-free survival (ANOVA; P = 0.0057) 
in ER-positive breast cancer patients (Figure 3A, 3B), but 
not in ER-negative tumors (data not shown). In this patient 
group, high expression levels of HSF1 also correlated with 
worse overall survival in node-negative subset (ANOVA; 
P = 0.00022; Figure 3C), showing that cases with high 
HSF1 have a significant mortality risk when compared with 
low level of HSF1 cases. We also assessed the prognostic 
value of HSF1 patients in untreated versus tamoxifen-
treated patients. High HSF1 expression is associated 
with shorter overall survival (ANOVA; P = 0.00049) in 
untreated population (Figure 3D) and with shorter relapse-
free survival for tamoxifen-treated patients (Figure 3E). 
These results indicate that targeting HSF1 may help prevent 
development of metastases in ER-positive patients.
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Multivariable Cox hazard analysis of HSF1 
expression with clinical variables showed that low HSF1 
expression was associated with good prognosis in all 
patients (overall survival (hazard ratio [HR] = 0.65; 95% 
CI = 0.47–0.89; P = 0.0083) and relapse-free survival 
(HR = 0.71; 95% CI = 0.51–1; P = 0.048) (Table 2). The 
other factors that retained significance in multivariable 
analysis were nodal status, tumor grade, age and tumor 
size (> 2 cm) for the overall survival. Tumor size (> 20 
mm) was the only significant factor for relapse-free 
survival (HR = 1.98; 95% CI = 1.5–2.62; P = 1.58e–06). 
These results further validate high HSF1 is an independent 
poor prognostic marker in ER-positive tumors using large 
cohorts of breast cancer patients.
DISCUSSION
Santagata et al, in their study of the Nurses Health 
Cohort, demonstrated that HSF1 is an independent 
prognostic marker in breast cancer in a TMA-based 
analysis using immunohistochemical methods [16]. 
However, their study was performed using a cocktail 
of three different antibodies to detect HSF1 protein in 
TMAs. More recently, a monoclonal antibody directed 
against HSF1 has become commercially available. The 
differences in isotope specificity of this antibody and the 
antibody-cocktail to HSF1 is not known. Apart from the 
differences in reagents, our study employed a surrogate 
endpoint, Oncotype DX assay, for analyzing prognostic 
impact. In our study, upregulation of HSF1 protein was 
independent of Oncotype DX scores. In order to confirm 
that differences observed could be attributed to technical 
and tissue sampling issues and not related to biological 
relevance, we further evaluated the role of HSF1 in breast 
cancer using publically available datasets. 
Analysis of the TCGA dataset showed that mutations 
were not common (0.2%); copy number alterations were 
noted in 14.8%, nearly 50% of which were amplification 
events. HSF1 amplification or upregulation of HSF1 was not 
associated with prognosis in all patients, or in ER-positive 
Table 1: Correlation of the immunohistochemistry findings with Oncotype Dx scores
Table 1 Nuclear Intensity Percentage positivity H-Score
Oncotype DX score 0 1 2 < 10% > 10% H < 70 H > 70
High 4 9 7 4 16 9 11
Intermediate 17 22 15 18 36 27 27
Low 36 36 15 38 49 57 30
Grand Total 57 67 37 60 101 93 68
Figure 1: Expression of HSF1 in breast cancer. Representative immunohistochemical staining pattern of primary breast tumors for 
HSF1 (New England BioLabs, #4356). Nuclear staining intensity is categorized as the following; (A) no nuclear staining &/or cytoplasmic 
staining only (0), (B) low level nuclear staining (1+), (C) strong nuclear staining (2+).
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Table 2: Multivariable analysis in ER+ patients for overall survival and relapse-free survival 
(Affymetrix datasets)
OS RFS
Variable HR (95% CI) P value* HR (95% CI) P value*
low HSF1 versus high HSF1 0.65 (0.47–0.89) 0.0083 0.71 (0.51–1) 0.048
LN- versus LN+ 0.48 (0.35–0.67) 1.93e-05 0.77 (0.57–1.03) 0.079
Grade 3 versus 1 + 2 1.5 (1.05–2.15) 0.025 1.25 (0.92–1.7) 0.148
Age > 50yrs versus < 50yrs 1.49 (1.05–2.13) 0.025 0.82 (0.62–1.1) 0.18
Tumor size > 20 mm versus < 20 mm 2.07 (1.48–2.9) 2.54e-05 1.98 (1.5–2.62) 1.58e–06
Figure 2: The cBio cancer genomics portal analysis. Copy number alterations (CNAs) and Mutations of HSF1 in TCGA breast 
cancer dataset. (A) individual genes are represented as rows, individual cases or patients are represented as columns, and glyphs and/ 
or color-coding is used to compactly summarize distinct genomic alterations, including somatic mutations and copy number alterations 
(CNAs), (B) correlation of CNAs with HSF1 expression (RNA-seq), (C) the pie chart showing the frequency of genomic alterations and 
mutations, (D) mutation details for HSF1, (E) the pie chart showing the frequency of upregulated or downregulated gene expression, (F) 
correlation of methylation status (HM450) with mRNA expression (RNA-seq) of HSF1.
Oncotarget84243www.impactjournals.com/oncotarget
or ER-negative subsets. However, it is recognized that the 
TCGA dataset has limited followup/survival information, 
so we further analyzed the prognostic relevance of HSF1 
in breast cancer in a publically available large (n = 1881) 
Affymetrix-based gene expression dataset. These analyses 
showed upregulation of HSF1 was associated with shorter 
overall survival and relapse-free survival in ER-positive, 
but not in ER-negative patients. High HSF1 expression was 
significantly associated with worse outcome in treatment-
naïve tumors and in node-negative tumors. Cheng et al. 
have also analyzed the role of HSP90, and HSF1 in 
multiple data sets including many that are included in the 
current study. They failed to observe a significant impact 
of HSF1 in their analysis. The major differences in the two 
studies are the number of patients analyzed and analytical 
methods. They focused on subsets of patients with highest 
(top 10% or 25%) and lowest expression and did not find an 
impact once clinical confounding features were included. In 
contrast, our multivariable analysis that included age, tumor 
grade ER status, and treatment type confirmed that high 
HSF1 is an independent factor of poor clinical outcome in 
ER-positive breast cancer. Collectively, this data makes a 
strong case for a role of HSF1 in endocrine resistance and 
recurrence/metastasis. 
HSF1 is a key transcription factor in the regulation 
of cellular homeostasis and modulates protein folding, 
stability, and protein-protein interactions. In response to 
a variety of stresses, HSF1 binds to the promoter regions 
of heat shock protein genes and drives transcription of 
these genes including HSP90 and HSP70. Although 
HSF1 supports the survival of normal cells under 
stress, aberrant upregulation of HSF1 has been shown 
to promote tumor cell survival and cancer progression. 
Therefore, HSP90 inhibitors can serve as potential target 
for therapeutics for patients with high HSF1 in ER-
positive breast cancer. However, HSF1 can serve as a hub 
regulating a transcriptional program that can be distinct 
from heat shock protein network [12]. Therefore, better 
understanding of this program is necessary to target HSF1 
therapeutically using agents other than HSP90 inhibitors.
In summary, high expression of HSF1 mRNA was 
associated with both shorter relapse-free survival and 
overall survival in patients with ER-positive breast cancer. 
Identification of high HSF1 could stratify patients at greater 
risk for recurrence/metastasis development independently 
of Oncotype DX. Therapies that can downregulate HSF1 
need to be explored to prevent recurrence/metastasis 
development in ER-positive breast cancer.
Figure 3: Kaplan-Meier analysis using the Affymetrix data sets (GOBO). Ten-year (A) overall survival (OS) and (B) relapse-
free survival (RFS) for ER-positive tumors, (C) ER-positive and lymph node (LN)-negative tumors, (D) OS for untreated tumors, and 
(E) RFS for tamoxifen (Tam)-treated tumors. The expression analysis was stratified into two quantiles based on HSF1 expression; low 
expression (gray) and high expression (red).
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MATERIALS AND METHODS
Tissue microarray patients
All protocols were reviewed and approved by the 
Institutional Review Board of Indiana University. All 
archival formalin-fixed, paraffin-embedded tumor blocks 
in this study were from patients with ER-positive (greater 
than 1% expression as per ASCO-CAP guidelines) breast 
carcinomas at the Indiana University Health Pathology 
Lab (IUHPL). The tissue samples consisted of a tissue 
microarray (TMA) containing duplicate (1mm) cores. On 
all of these 210 tumors, Oncotype DX recurrence score 
was available. The distribution of the Oncotype DX scores 
in the TMA series was 120 low; 65 intermediate; and 25 
high scores (Supplementary Table S1).
Immunohistochemistry
Archival formalin-fixed, paraffin-embedded TMA 
blocks were cut at 4µ thickness. After deparaffinization 
and hydration, sections were incubated with the primary 
antibody. The HSF1 rabbit polyclonal antibody (New 
England BioLabs #4356) was diluted to 1/100 stained using 
the BOND-III (Leica Biosystems, Melbourne) automated 
stainer with Bond Polymer Refine Detection system (Leica 
Biosystems Newcastle, DS9800), Bond Diluent (Leica 
Biosystems Newcastle, AR9352) and ER2 reagent (Leica 
Biosystems Newcastle, AR9640). The ER2 solution was 
incubated for 20 minutes followed by a 15minute incubation 
with the diluted antibody. HSF1 scoring was based on 
H-Score method combining percentage and intensity. 
Analysis of the cancer genome atlas (TCGA)
Somatic mutation rate, DNA copy number 
alterations (CNAs), mRNA, and methylation status for 
HSF1 were analyzed using the cBioPortal for Cancer 
Genomics (http://cbioportal.org). The portal is a Web 
resource to analyze complex cancer genomics data 
including genetic, epigenetic, gene expression and 
proteomic events [17, 18]. Tumors with CNA and RNA-
sequencing data available were analyzed. For the survival 
analysis, cases with and without amplifications were 
identified and their survival data downloaded. Log-rank 
analysis was performed using Kaplan Meier method using 
the R statistical package.
Analysis of publicly available datasets 
Expression of HSF1 was analyzed based on ER status, 
molecular subtypes, and other clinicopathological parameters 
using the datasets from the gene expression-based outcome 
for breast cancer online algorithm (GOBO) [19]. GOBO is 
a web-based analysis tool that utilizes 11 publicly available 
Affymetrix U133A gene expression data curated from 
1881 breast cancer patients with associated stage, grade, 
nodal status, and intrinsic molecular classification [19]. Of 
all 1881 tumors, the groups were distributed as follows: 
a) ER-positive patients (n = 1225) of which 326 patients 
treated with tamoxifen alone while the remainder 927 did 
not receive systemic therapy and b) ER-negative patients 
(n = 395). Clinical characteristics of individual datasets 
were described previously [19]. Association of outcome 
was stratified into the two quantiles based on HSF1 gene 
expression level for each patient cohort with overall survival 
or relapse-free survival as endpoints and 10-year censoring 
in the above groups. The Kaplan-Meier survival analysis 
was calculated using Cox proportional hazard model, and the 
score test of the proportional hazard model was equivalent 
to the log-rank test.
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